Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
29049 results about "Cancer research" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cancer research is research into cancer to identify causes and develop strategies for prevention, diagnosis, treatment, and cure. Cancer research ranges from epidemiology, molecular bioscience to the performance of clinical trials to evaluate and compare applications of the various cancer treatments. These applications include surgery, radiation therapy, chemotherapy, hormone therapy, immunotherapy and combined treatment modalities such as chemo-radiotherapy. Starting in the mid-1990s, the emphasis in clinical cancer research shifted towards therapies derived from biotechnology research, such as cancer immunotherapy and gene therapy.
Anti-PD-L1 antibodies, compositions and articles of manufacture
Owner:F HOFFMANN LA ROCHE & CO AG
Promoter for regulating expression of foreign genes
InactiveUS7125978B1Regulate expressionSugar derivativesOther foreign material introduction processesOrganismFhit gene
The present invention relates to a promoter for regulating expression of foreign genes in transgenic organisms, which comprises a promoter having the identifying characteristics of a promoter having a sequence selected from the group consisting of sequences set forth in SEQ ID NOS:1 to 3 and functional fragments or derivatives thereof, wherein said promoter is adapted to be operationally located with respect to said foreign gene for expression of said gene.
Owner:MEDICAGO INC
Method of treating androgen independent prostate cancer
The present invention is directed to a method treating prostate cancer. The method comprises administering to a patient in need thereof at least one compound selected from N-methyl-Δ3,3′-dihydroindole-2,2′ diketone; N-1-(β-D-O-triacetyl-xylopranosyl)-Δ3,3′-dihydroindole-2,2′ diketone; and N-1-(β-D-O-triacetyl-xylopranosyl)-N′-methyl-Δ3,3′-dihydroindole-2,2′ diketone. Preferably the compound is in an amount sufficient to inhibit growth, invasion, and / or metastasis of prostate cancer cells.
Owner:NATROGEN THERAPEUTICS INT
Methods and compositions for selecting siRNA of improved functionality
InactiveUS20050255487A1Improve efficiencyGood curative effectOrganic active ingredientsGenetic material ingredientsGene silencingSilencing gene
Owner:THERMO FISHER SCIENTIFIC INC
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and / or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.
Owner:3M INNOVATIVE PROPERTIES CO
Compositions and methods for treating and diagnosing cancer
InactiveUS20060019256A1Reduce the amount requiredMicrobiological testing/measurementAntiinfectivesSolid tumorCancer research
The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles associated with solid tumor stem cells, as well as novel stem cell cancer markers useful for the diagnosis, characterization, and treatment of solid tumor stem cells.
Owner:RGT UNIV OF MICHIGAN
Treatment with anti-VEGF antibodies
InactiveUS20050186208A1Effective approachExtended durationBiocidePeptide/protein ingredientsAbnormal tissue growthAnti vegf antibody
This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
Owner:GENENTECH INC
Compositions for targeting the vasculature of solid tumors
InactiveUS6051230AEffectively compete for bindingReduce TEC-4 or TEC-11 bindingHybrid immunoglobulinsPeptide/protein ingredientsAntigenCell Surface Antigens
The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
InactiveUS20120244133A1Increase the number ofBiocideArtificial cell constructsTumour tissueCell culture media
An embodiment of the invention provides a method of promoting regression of cancer in a mammal comprising obtaining a tumor tissue sample from the mammal; culturing the tumor tissue sample in a first gas permeable container containing cell medium therein; obtaining tumor infiltrating lymphocytes (TIL) from the tumor tissue sample; expanding the number of TIL in a second gas permeable container containing cell medium therein using irradiated allogeneic feeder cells and / or irradiated autologous feeder cells; and administering the expanded number of TIL to the mammal. Methods of obtaining an expanded number of TIL from a mammal for adoptive cell immunotherapy are also provided.
Owner:UNITED STATES OF AMERICA +1
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
ActiveUS20130309250A1Reduces and suppresses signalingReliable responseImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntigenTissue sample
The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1 / PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
Owner:BRISTOL MYERS SQUIBB CO
Pyrazole compounds useful as protein kinase inhibitors
This invention describes novel pyrazole compounds of formula IIIa: wherein R1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx, Ry, R2; and R2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
Owner:VERTEX PHARMA INC
Anti-TIM-3 antibody
Owner:KYUSHU UNIV +1
Substituted Benzoazepines As Toll-Like Receptor Modulators
Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and / or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease.
Owner:ARRAY BIOPHARMA +1
Functional and hyperfunctional siRNA directed against Bcl-2
InactiveUS20050245475A1Improve efficiencyGood curative effectOrganic active ingredientsGenetic material ingredientsSilencing geneCancer research
Owner:THERMO FISHER SCIENTIFIC INC
Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
Integration of costimulatory signaling domains within a tumor targeting chimeric antigen receptor (CAR), such as the IL13Rα2 specific IL13-zetakine (IL13ζ), enhances T cell-mediated responses against tumors even in the absence of expressed ligands for costimulatory receptors.
Owner:CITY OF HOPE
RNA engineered t cells for the treatment of cancer
ActiveUS20140227237A1Reduce riskLimited half-lifeBiocideVirusesAntigen receptorChimeric antigen receptor
The present invention relates to compositions and methods for generating RNA Chimeric Antigen Receptor (CAR) transfected T cells. The RNA-engineered T cells can be used in adoptive therapy to treat cancer.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Compositions and methods for treating and diagnosing cancer
InactiveUS20070105133A1High of deathHigh riskMicrobiological testing/measurementBiological material analysisCancer metastasisSolid tumor
The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles and signatures associated with solid tumor stem cells, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of solid tumor stem cells. More particularly, the present invention identifies two profiles of cancer stem cells useful for the diagnosis, characterization, and treatment of cancer and cancer metastases. The invention also provides a variety of reagents such as stem cell gene signatures for use in the diagnosis and management of cancer.
Owner:RGT UNIV OF MICHIGAN
Anti-PD1 Antibodies and their Use as Therapeutics and Diagnostics
ActiveUS20150079109A1Improve the level ofHigh expressionNervous disorderAntiviralsAntiendomysial antibodiesInfectious Disorder
Owner:BEIGENE SWITZERLAND GMBH
Compositions and methods for treating and diagnosing cancer
InactiveUS20070099209A1Reduce the amount requiredBioreactor/fermenter combinationsBiological substance pretreatmentsCancer geneSolid tumor
The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles associated with solid tumor stem cells, as well as novel stem cell cancer gene signatures useful for the diagnosis, characterization, prognosis and treatment of solid tumor stem cells.
Owner:RGT UNIV OF MICHIGAN
Rodent HER2 tumor model
The invention concerns HER<HIL><PDAT>2< / BOLD><PDAT>-transgenic non-human mammals, animal models for screening drug candidates for the treatment of diseases and disorders associated with the overexpression of HER<HIL><PDAT>2< / BOLD><PDAT>. In particular, the invention concerns animal models designed to test drug candidates for the treatment of HER<HIL><PDAT>2< / BOLD><PDAT>-overexpressing cancers, including breast cancer, that are not responding or poorly responding to current treatments.< / PTEXT>
Owner:SAN VALLEY SYST +1
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
ActiveUS7932260B2Inhibit growth and proliferationInhibit growthBiocideSenses disorderLeukocyte functionWhite blood cell
Owner:ICOS CORP
Antibody affinity engineering by serial epitope-guided complementarity replacement
InactiveUS20050008625A1Comparable and superior in bioactivityBiocideGenetic material ingredientsCell basedCancer research
This invention provides for a novel means for obtaining human idiologs for any non-human antibody to any target by epitope guided replacement of variable regions using competitive cell-based methods in which the competitor can be either the reference antibody or a ligand that binds to the same epitope on the target as the reference antibody.
Owner:KALOBIOS PHARMA
Micrornas and uses thereof
Described herein are novel polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.
Owner:ROSETTA GENOMICS
Degraded agonist antibody
InactiveUS20040242847A1Excellent antigen-binding propertyExcellent agonist activityPeptide/protein ingredientsAntibody mimetics/scaffoldsDiseaseAntiendomysial antibodies
The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking a cell surface molecule(s) to thereby serve as an agonist. The modified antibody can be used as a signal transduction agonist and, therefore, useful as a preventive and / or remedy for various diseases such as cancer, inflammation, hormone disorders and blood diseases.
Owner:CHUGAI PHARMA CO LTD
Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma
InactiveUS20020012665A1Avoiding and decreasing and resistanceOrganic active ingredientsIn-vivo radioactive preparationsFactor iiBiological activation
The present invention discloses combined therapies for treating hematologic malignancies, including B cell lymphomas and leukemias or solid non-hematologic tumors, comprising administration of anti-cytokine antibodies or antagonists to inhibit the activity of cytokines which play a role in perpetuating the activation of B cells. The administration of such antibodies and antagonists, particularly anti-IL10 antibodies and antagonists, is particularly useful for avoiding or decreasing the resistance of hematologic malignant cells or solid tumor cells to chemotherapeutic agents and anti-CD20 or anti-CD22 antibodies. The invention also provides combination therapies for solid tumors having B cell involvement comprising the administration of an anti-cytokine antibody and a B cell depleting antibody such as RITUXAN(R).
Owner:BIOGEN INC
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM') of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM' allows the use of an immunoenzymatic assay for their detection.
Owner:ER SQUIBB & SONS INC
EGFR mutations
The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and / or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment.
Owner:GENENTECH INC
Generation and application of universal T cells for B-ALL
InactiveUS20070036773A1Hinder recognitionEnhanced siRNA effectBiocideGenetic material ingredientsAntigenNatural Killer Cell Inhibitory Receptors
The present invention is directed to universal T cells and their use in treating diseases and other physiological conditions. More specifically, the present invention is directed to universal T cells and their use in treating treating B-lineage acute lymphoblastic leukemia (B-ALL) in particular and malignancy in general. The universal T cells contain (i) nucleic acid encoding a chimeric antigen receptor (CAR) to redirect their antigen specificity and effector function and (ii) nucleic acids encoding shRNA and / or siRNA molecules to down-regulate cell-surface expression of T cell classical HLA class I and / or II genes to avoid recognition by recipient T cells. The universal T cells may also contain a nucleic acid encoding a non-classical HLA gene, such as an HLA E gene to enforce expression of HLA E genes and / or an HLA G gene to enforce expression of HLA G genes, to avoid recognition by recipient NK cells. The universal T cells may further contain a nucleic acid encoding a selection-suicide gene.
Owner:CITY OF HOPE
Generation of modified molecules with increased serum half-lives
InactiveUS20020142374A1Antibody mimetics/scaffoldsImmunoglobulins against cytokines/lymphokines/interferonsSerum igeHalf-life
In accordance with the present invention, there are provided methods for the extension of serum half-lives of proteinaceous molecules, particularly antibody molecules, and compositions of molecules modified in accordance with the methods of the invention. In accordance with a first aspect of the present invention, there is provided a method of modifying the half-life of an antibody through providing an antibody containing an FcRn binding domain or the genes encoding such antibody and physically linking the antibody or the antibody as encoded to a second FcRn binding domain. In accordance with a second aspect of the present invention, there is provided a molecule that contains at least two distinct FcRn binding moieties.
Owner:ABQENIX INC
Novel lipid formulations for delivery of therapeutic agents to solid tumors
ActiveUS20110076335A1Improve effectivenessFavorable toxicity profileOrganic active ingredientsSpecial deliveryLipid formationLipid particle
The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and / or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and / or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.
Owner:ARBUTUS BIOPHARMA CORPORAT ION
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com